重组干扰素α2和西咪替丁在晚期恶性黑色素瘤患者中的作用
Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
作者信息
Mughal T I, Robinson W A, Thomas M R, Spiegel R
机构信息
Melanoma Clinic Research Center, University of Colorado Health Sciences Center Denver 80262.
出版信息
J Cancer Res Clin Oncol. 1988;114(1):108-9. doi: 10.1007/BF00390495.
Abstract
Following recent reports suggesting that the addition of cimetidine to interferon may enhance response rates in patients with metastatic malignant melanoma, we have completed a Phase II study of the use of recombinant alpha 2 interferon and cimetidine in patients with advanced malignant melanoma and who had progressive disease following interferon therapy alone. We observed two partial responses, no complete responses, and two patients had stable disease. Toxicity encountered was analogous to that of interferon alone. We conclude that the additional of cimetidine to alpha interferon is not beneficial in the treatment of advanced metastatic malignant melanoma.
摘要
最近有报道称，在干扰素中添加西咪替丁可能会提高转移性恶性黑色素瘤患者的缓解率，在此之后，我们完成了一项II期研究，该研究针对晚期恶性黑色素瘤患者使用重组α2干扰素和西咪替丁，这些患者在仅接受干扰素治疗后病情仍进展。我们观察到2例部分缓解，无完全缓解，2例患者病情稳定。所遇到的毒性与单独使用干扰素时类似。我们得出结论，在α干扰素中添加西咪替丁对晚期转移性恶性黑色素瘤的治疗并无益处。
相似文献
1
Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
J Cancer Res Clin Oncol. 1988;114(1):108-9. doi: 10.1007/BF00390495.
2
Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma.
J Cancer Res Clin Oncol. 1987;113(5):459-65. doi: 10.1007/BF00390040.
3
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma.
J Cancer Res Clin Oncol. 1987;113(3):273-8. doi: 10.1007/BF00396385.
5
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD008955. doi: 10.1002/14651858.CD008955.pub2.
6
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Br J Dermatol. 2025 Jan 24;192(2):316-326. doi: 10.1093/bjd/ljae401.
7
Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis.
J Cancer Res Clin Oncol. 2006 Aug;132(8):499-504. doi: 10.1007/s00432-006-0095-7. Epub 2006 Apr 4.
8
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3.
9
Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.
10
Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.
J Cancer Res Clin Oncol. 1988;114(1):95-100. doi: 10.1007/BF00390492.
引用本文的文献
1
Extracellular matrix shapes cancer stem cell behavior in breast cancer: a mini review.
Front Immunol. 2025 Jan 9;15:1503021. doi: 10.3389/fimmu.2024.1503021. eCollection 2024.
2
Anorectal malignant melanoma: report of a case.
Surg Today. 1997;27(8):753-6. doi: 10.1007/BF02384991.
3
Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
Med Oncol. 1995 Mar;12(1):35-40. doi: 10.1007/BF01571406.
4
Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.
Clin Exp Metastasis. 1993 May;11(3):275-83. doi: 10.1007/BF00121170.
5
Interferon-alpha in malignant and viral diseases. A review.
Drugs. 1993 Feb;45(2):177-211. doi: 10.2165/00003495-199345020-00003.
6
Rational use of antihistamines in allergic dermatological conditions.
Drugs. 1989 Oct;38(4):634-44. doi: 10.2165/00003495-198938040-00009.
本文引用的文献
1
Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267.
J Immunol. 2015 Sep 1;195(5):1911-20.
2
Virus interference. I. The interferon.
Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67. doi: 10.1098/rspb.1957.0048.
3
Reporting results of cancer treatment.
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
4
Human leukocyte interferon and cimetidine for metastatic melanoma.
N Engl J Med. 1982 Oct 21;307(17):1080-1. doi: 10.1056/nejm198210213071716.
5
Immunological effects of recombinant interferon-alpha 2 in cancer patients.
J Biol Response Mod. 1983;2(6):516-27.
6
Interferons in the treatment of human cancer.
J Clin Oncol. 1984 Apr;2(4):336-52. doi: 10.1200/JCO.1984.2.4.336.
7
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
Ann Intern Med. 1982 May;96(5):549-56. doi: 10.7326/0003-4819-96-5-549.
8
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.
JAMA. 1982 Mar 26;247(12):1718-22.
9
Successful tumour immunotherapy with cimetidine in mice.
Lancet. 1981 Mar 21;1(8221):636-8. doi: 10.1016/s0140-6736(81)91554-3.
10
Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.
Immunobiology. 1986 Sep;172(3-5):275-82. doi: 10.1016/S0171-2985(86)80109-7.
Zotero 插件